High Viral Specific Antibody Convalescent Plasma Effectively Neutralizes SARS-CoV-2 Variants of Concern

The ongoing evolution of SARS-Co-V2 variants to omicron severely limits available effective monoclonal antibody therapies. Effective drugs are also supply limited. Covid-19 convalescent plasma (CCP) qualified for high antibody levels effectively reduces immunocompetent outpatient hospitalization. Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Maggie, Beck, Evan J., Laeyendecker, Oliver, Eby, Yolanda, Tobian, Aaron AR, Caturegli, Patrizio, Wouters, Camille, Chiklis, Gregory R., Block, William, McKie, Robert, Joyner, Michael, Wiltshire, Timothy D., Dietz, Allan B., Gniadek, Thomas J., Shapiro, Arell, Yarava, Anusha, Lane, Karen, Hanley, Daniel, Bloch, Evan M., Shoham, Shmuel, Cachay, Edward R., Meisenberg, Barry R., Huaman, Moises A., Fukuta, Yuriko, Patel, Bela, Heath, Sonya L., Levine, Adam C., Paxton, James H., Anjan, Shweta, Gerber, Jonathan M., Gebo, Kelly A., Casadevall, Arturo, Pekosz, Andrew, Sullivan, David J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8902868/
https://www.ncbi.nlm.nih.gov/pubmed/35262085
http://dx.doi.org/10.1101/2022.03.01.22271662

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8902868/
https://www.ncbi.nlm.nih.gov/pubmed/35262085
http://dx.doi.org/10.1101/2022.03.01.22271662

Ejemplares similares